Whole-exome sequencing to identify novel somatic mutations in squamous cell lung cancers.

Squamous cell lung cancer is a major histotype of non-small cell lung cancer (NSCLC) that is distinct from lung adenocarcinoma. We used whole-exome sequencing to identify novel non-synonymous somatic mutations in squamous cell lung cancer. We identified 101 single-nucleotide variants (SNVs) including 77 non-synonymous SNVs (67 missense and 10 nonsense mutations) and 11 INDELs causing frameshifts. We also found four SNVs located within splicing sites. We verified 62 of the SNVs (51 missense, 10 nonsense and 1 splicing-site mutation) and 10 of the INDELs as somatic mutations in lung cancer tissue. Sixteen of the mutated genes were also mutated in at least one patient with a different type of lung cancer in the Catalogue of Somatic Mutation in Cancer (COSMIC) database. Four genes (LPHN2, TP53, MYH2 and TGM2) were mutated in approximately 10% of the samples in the COSMIC database. We identified two missense mutations in C10orf137 and MS4A3 that also occurred in other solid-tumor tissues in the COSMIC database. We found another somatic mutation in EP300 that was mutated in 4.2% of the 2,020 solid-tumor samples in the COSMIC database. Taken together, our results implicate TP53, EP300, LPHN2, C10orf137, MYH2, TGM2 and MS4A3 as potential driver genes of squamous cell lung cancer.

[1]  F. Westermann,et al.  Cep63 recruits Cdk1 to the centrosome: implications for regulation of mitotic entry, centrosome amplification, and genome maintenance. , 2011, Cancer research.

[2]  B. Howard,et al.  The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.

[3]  D. Livingston,et al.  Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300 , 2003, Science.

[4]  P. Hainaut,et al.  Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. , 2010, Carcinogenesis.

[5]  A. Borczuk,et al.  Genomics of lung cancer. , 2009, Proceedings of the American Thoracic Society.

[6]  J. Espinosa,et al.  Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. , 2001, Molecular cell.

[7]  Tsutomu Ohta,et al.  Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy , 2008, Proceedings of the National Academy of Sciences.

[8]  Jukka-Pekka Mecklin,et al.  Somatic mutations and germline sequence variants in patients with familial colorectal cancer , 2010, International journal of cancer.

[9]  D. Livingston,et al.  p300/MDM2 complexes participate in MDM2-mediated p53 degradation. , 1998, Molecular cell.

[10]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[11]  P Baas,et al.  Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  D. Livingston,et al.  Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation , 1998, Nature.

[13]  Y. Yatabe,et al.  Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib , 2007, British Journal of Cancer.

[14]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[15]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[16]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[17]  D. Ettinger,et al.  Metastatic non-small cell lung cancer , 1993 .

[18]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[19]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Meyerson,et al.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. , 2011, Cancer discovery.

[21]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[22]  J. Kutok,et al.  Human HTm4 is a hematopoietic cell cycle regulator. , 2002, The Journal of clinical investigation.

[23]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[24]  M. Meyerson,et al.  Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer , 2011, PloS one.

[25]  M. Ladanyi,et al.  Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations , 2012, Clinical Cancer Research.

[26]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[27]  Niruthika Sritharan,et al.  Genomic landscape of non-small-cell lung cancer in smokers and never-smokers , 2013, Thorax.

[28]  Levi A Garraway,et al.  Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. , 2007, Cancer research.

[29]  D. Livingston,et al.  Binding and modulation of p53 by p300/CBP coactivators , 1997, Nature.

[30]  K. Gardner,et al.  Recruitment of p300/CBP in p53-Dependent Signal Pathways , 1997, Cell.

[31]  J. Kutok,et al.  Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues , 2009, Journal of cellular and molecular medicine.

[32]  H. Ozçelik,et al.  Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines , 2011, BMC Medical Genomics.

[33]  Raffaella Faraoni,et al.  CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity , 2012, Molecular Cancer Therapeutics.

[34]  David Newsome,et al.  Gene Dosage–Dependent Embryonic Development and Proliferation Defects in Mice Lacking the Transcriptional Integrator p300 , 1998, Cell.

[35]  A. McCullough Comprehensive genomic characterization of squamous cell lung cancers , 2013 .